Introgen Therapeutics and researchers at the University of Texas M. D. Anderson Cancer Center have reported that MDA-7, the active component of INGN 241, effectively kills cancer cells that are resistant to cisplatin, one of the most commonly used chemotherapeutic agents.
Preclinical studies also identified a novel defect in a protein degradation pathway in the cisplatin- resistant cells. Significantly, this defect enhances the activity of INGN 241, suggesting that INGN 241 may have particular utility in treating cancers that do not respond to cisplatin.
The studies were designed to determine if INGN 241 could effectively kill cisplatin-resistant cancer cells. The results show that INGN 241 had potent cell killing effects in both cisplatin-sensitive and cisplatin-resistant cells.